The presentation highlights the Company's key achievements and recent commercial activities:
- Current negotiations with #1 global animal health company, Zoetis Inc, regarding a commercial agreement for the worldwide development, distribution and marketing of Detach(R)
- Submission of the Company's dossier to the Australian Pesticides and Veterinary Medicines Authority (APVMA), seeking regulatory approval to register Detach(R) for commercial marketing in Australia
- Preparing Detach(R) for commercial launch in the Australian market
- Revenue up 12.6% to $3.2 million, including the receipt of milestone payments under the Zoetis Research Evaluation and License Option Agreement, receipt of the 2015-16 R&D tax rebate and successful grant funding applications
The presentation also includes a status update on the Company's efforts to develop its product pipeline, extending from its core application to control diarrhoea in pigs, to human gastrointestinal conditions such as Irritable Bowel Syndrome, Inflammatory Bowel Disease and Traveller's Diarrhoea.
To view the presentation, please visit:
About Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(R) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies. Please see http://www.anataralifesciences.com for further background.
Anatara Lifesciences Ltd